Priority ERP fundamentally changed how Fore Biotherapeutics manages its financial operations. What once required manual journal entries, spreadsheet consolidation, and repetitive budget tracking is now managed automatically within a single integrated platform.
Budget reporting has become significantly faster, committed spending is visible in real time, and finance leaders can access consolidated information across all companies with a single click. The result is greater confidence in financial data, fewer manual errors, and more time to focus on supporting the business.
Multi-company budget management
Three companies are now managed through one centralized budgeting process.
Consolidated budget versus actual reports are generated with a single click, eliminating the manual Excel consolidation previously required.
Real-time budget control
Purchase orders are automatically included in budget usage as soon as they are created.
Finance teams now have immediate visibility into committed spending instead of waiting until invoices arrive.
Significant time savings
Automating budget tracking has saved the finance team many hours every month.
Manual journal entry re-keying and spreadsheet maintenance have been virtually eliminated, reducing administrative effort and improving reporting accuracy.
“With Priority, we saved many monthly hours by automating our budget tracking process.” – Bat-El Reuven, Director of Finance, Fore Biotherapeutics
Better financial decision-making
Finance leaders now have immediate access to accurate budget information across all entities, enabling faster, more informed decisions based on current financial data rather than manually prepared spreadsheets.
A higher return on investment
For Fore Biotherapeutics, Priority ERP delivered more than process improvements; it transformed the role of the finance team. By replacing manual work with automated workflows and real-time reporting, the team can spend less time maintaining spreadsheets and more time supporting the company's mission to develop treatments for patients with rare cancers.